AlgoTx
is a France-based biotechnology company that develops novel therapeutics to treat chemotherapy pain... Read moreAlgoTx
is a France-based biotechnology company that develops novel therapeutics to treat chemotherapy pain... Read more
News
Feb 19, 2025
Pharmabiz
AlgoTx: AlgoTherapeutix announces results of its phase 2 'ACT' trial of ATX01 in chemotherapyinduced peripheral neuropathy
Feb 18, 2025
Endpoints News
AlgoTx: Algo's topical pain treatment fails Phase 2 study with overperforming placebo
Feb 18, 2025
BioSpace
AlgoTx: AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex's Journavx Approval
Sep 24, 2024
PharmaTimes
AlgoTx: AlgoTx completes pivotal phase 2 trial for ground-breaking CIPN treatment
Sep 24, 2024
GlobalNewswire
Press Release: AlgoTx : AlgoTx Announces "Last Patient Last Visit" in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
Sep 12, 2023
Life Care News
AlgoTx: AlgoTx Announces First Patients Dosed in US and European
Mar 30, 2023
FinanzNachrichten
AlgoTx: AlgoTx Progresses ATX01 in Two Indications
Mar 29, 2023
Pharamceutical Technology
AlgoTx: AlgoTx unveils plans for Phase II trial for rare chronic condition
Sep 02, 2022
Clinical Trials Arena
AlgoTx: AlgoTx begins Phase II trial of neuropathy pain relief treatment
Jun 09, 2022
FinanzNachrichten
AlgoTx: AlgoTherapeutix SAS: AlgoTx's ATX01 Granted Fast Track Designation by FDA for Chemotherapy-Induced Neuropathic Pain
